Trial
NCT00765102
Trial of Romidepsin and Bortezomib for Multiple Myeloma
Phase IITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Celgene
Collaborators
—
Condition
Multiple Myeloma
Intervention
Bortezomib
Why stopped
There was a change in the Sponsor's research strategy; safety concerns were not a factor.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-11-25